Patents by Inventor Vanitha Ramakrishnan

Vanitha Ramakrishnan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080260732
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 7, 2007
    Publication date: October 23, 2008
    Inventors: VANITHA RAMAKRISHNAN, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Publication number: 20080260740
    Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
    Type: Application
    Filed: June 12, 2008
    Publication date: October 23, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Yongke ZHANG, Vanitha RAMAKRISHNAN, Debbie LAW
  • Publication number: 20080181903
    Abstract: The present application describes a conjugate between a natriuretic peptide, such as urodilatin, and the constant region of an immunoglobulin or a fragment thereof. Also described are compositions comprising the conjugate and methods for using the conjugate.
    Type: Application
    Filed: December 19, 2007
    Publication date: July 31, 2008
    Applicant: PDL BioPharma, Inc.
    Inventors: Vinay Bhaskar, Robert Bryan Dubridge, Vanitha Ramakrishnan, Hans-Michael Jantzen
  • Publication number: 20080175846
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: September 13, 2007
    Publication date: July 24, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Vinay Bhaskar, Agustin de la Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Patent number: 7399469
    Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: July 15, 2008
    Assignee: PDL BioPharma, Inc.
    Inventors: Yongke Zhang, Vanitha Ramakrishnan, Debbie Law
  • Publication number: 20080160012
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: August 10, 2007
    Publication date: July 3, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Vinay BHASKAR, Agustin DE LA CALLE, Debbie LAW, Ingrid CARAS, Vanitha RAMAKRISHNAN, Richard MURRAY, Daniel AFAR, David POWERS
  • Publication number: 20080044840
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: August 10, 2007
    Publication date: February 21, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Vinay BHASKAR, Agustin DE LA CALLE, Debbie LAW, Ingrid CARAS, Vanitha RAMAKRISHNAN, Richard MURRAY, Daniel AFAR, David POWERS
  • Publication number: 20080026033
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 31, 2008
    Inventors: Vanitha Ramakrishnan, David Powers, Dale Johnson, Ursula Jeffry
  • Publication number: 20080026458
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 31, 2008
    Inventors: VANITHA RAMAKRISHNAN, David Powers, Dale Johnson, Ursula Jeffry, Vinay Bhaskar
  • Patent number: 7288248
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: October 30, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Vinay Bhaskar, Agustin de la Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Patent number: 7285268
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: October 23, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry
  • Patent number: 7276589
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: October 2, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Vanitha Ramakrishnan, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
  • Patent number: 7060271
    Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: June 13, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vanitha Ramakrishnan, Maria Amelia Escobedo, Larry J. Fretto
  • Publication number: 20060008415
    Abstract: The present invention is directed to stable protein derivatives, e.g., antibodies, antibody fragments or peptides, with at least one free thiol group coupled to N-acetyl-L-cysteine, N-ethyl-maleimide, or cysteine and the methods of making such derivatives. In addition, stable liquid pharmaceutical formulations comprising such proteins or their derivatives and stable lyophilized pharmaceutical formulations comprising such proteins are provided. The present invention is also directed to a method of making a stable Fab? fragment of an antibody and a method of controlling vascularization in injured or cancerous tissue comprising applying to the injured tissue one or more doses of the pharmaceutical formulations.
    Type: Application
    Filed: June 24, 2005
    Publication date: January 12, 2006
    Applicant: Protein Design Labs, Inc.
    Inventors: Elisabet Kaisheva, Supriya Gupta, Weichang Zhou, Robert Weinkam, Patrick Powers, Naichi Liu, Vanitha Ramakrishnan
  • Publication number: 20050260210
    Abstract: The present invention provides methods for direct killing of cancer cells using anti-?5?1 antibodies. Generally, the method comprises contacting a cancer cell that expresses ?5?1 on its surface with an anti-?5?1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-?5?1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
    Type: Application
    Filed: March 24, 2005
    Publication date: November 24, 2005
    Inventors: Vanitha Ramakrishnan, Vinay Bhaskar, Sun Ho, Richard Murray, Debbie Law
  • Publication number: 20050260212
    Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
    Type: Application
    Filed: March 25, 2005
    Publication date: November 24, 2005
    Inventors: Yongke Zhang, Vanitha Ramakrishnan, Debbie Law
  • Patent number: 6953874
    Abstract: The present invention relates to nonhuman transgenic animals in which the GP V gene has been modified. The invention is also useful for identifying agents that modulate the biological functions of GP V, including the screening and identification of potential therapeutic agents.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: October 11, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vanitha Ramakrishnan, David R. Phillips
  • Publication number: 20050163769
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: April 23, 2004
    Publication date: July 28, 2005
    Inventors: Vanitha Ramakrishnan, David Powers, Dale Johnson, Ursula Jeffry
  • Publication number: 20050054834
    Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
    Type: Application
    Filed: November 26, 2003
    Publication date: March 10, 2005
    Inventors: Vanitha Ramakrishnan, David Powers, Dale Johnson, Ursula Jeffry, Vinay Bhaskar
  • Patent number: 6762029
    Abstract: The present invention includes a novel subtype of the P2-purinergic receptor, referred to as the P2Y12 receptor. This receptor is expressed selectively in the platelets and brain, and couples to a pertussis toxin-sensitive G protein (Gi). Nucleic acids encoding the receptor and associated screening and therapeutic methods are also disclosed.
    Type: Grant
    Filed: December 26, 2000
    Date of Patent: July 13, 2004
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Pamela B. Conley, Hans-Michael Jantzen, Vanitha Ramakrishnan-DuBridge, David Jay Julius, Gunther Hollopeter